Physician profile
Gianette Ruvalcaba
NPI 1265987481
$1,231.04
in general payments reported to CMS, 2019-2025
14 companies · $37.49 in 2025
The $37.49 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $420 · 2022: $399 · 2023: $256 · 2024: $118 · 2025: $37.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $411.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $377.42 | 2021-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $165.94 | 2021-2023 | Farxiga |
| Glaxosmithkline, LLC. | $163.20 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $106.88 | 2022-2023 | |
| Cleerly, INC. | $102.49 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Boston Scientific Corporation | $59.08 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.79 | 2022 | |
| Abbvie INC. | $45.03 | 2021 | |
| Horizon Therapeutics Plc | $44.40 | 2022 | |
| Amgen INC. | $37.49 | 2025 | Repatha |
| Lilly USA, LLC | $22.19 | 2022 | |
| Abbott Laboratories | $21.99 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.64 | 2021 | |
| Heartflow, INC. | $15.50 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gianette Ruvalcaba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.